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P U B L I S H E D B Y E L S E V I E R I N C .LettersPregnancy Complications
in Women With Heart
Disease Conceiving With
Fertility TherapyA growing number of women seek infertility treat-
ment with assisted reproductive technologies (ART),
such as in vitro fertilization (IVF) or intrauterine
insemination (IUI), in conjunction with ovarian
stimulation treatments (1). Although ART improve the
chances of successful pregnancy, there are potential
risks for the mother and offspring, including ovarian
hyperstimulation syndrome (OHSS), venous throm-
bosis, multiple gestations, pre-eclampsia, and pre-
term delivery (1). Women with heart disease have an
increased baseline risk of these obstetric and perinatal
complications (2,3). They may not tolerate additional
risks imposed by ART. However, complications in
pregnant women with heart disease treated with ART
have not been described, despite parallel trends of
delayed childbearing and increasing prevalence of
heart disease among reproductive-aged women.
Therefore, we aimed to describe adverse outcomes in a
series of pregnant women with heart disease treated
with ART.
Medical records of women followed in the Preg-
nancy and Heart Disease Program at our center and
enrolled in our long-standing pregnancy outcomes
study were reviewed to identify use of ART between
September 2007, and August 2013. Information on
cause of infertility, type of ART, superovulation
protocols, and ART complications was obtained by
self-report from each participant via telephone or
face-to-face interview. Qualitative comparisons of the
frequency of adverse outcomes were made using data
from published reference populations.
Of the 20 women with 22 pregnancies included,
15 (75%) were white, with a mean age of 37  4 years.
Fifteen pregnancies (68%) were in women with a
congenital heart defect, and 7 (32%) with acquired
heart disease. Most pregnancies were ﬁrst births
(nulliparity, 64%), and 2 (9%) were multiples. Preg-
nancy was achieved by IUI without hormonal
stimulation (n ¼ 1), IUI with hormonal stimulation(n ¼ 3), and IVF including cycles using donor oocytes
(n ¼ 18).
All pregnancies resulted in live births, except 1
that was electively terminated at 17 weeks due to
fetal omphalocele. Overall, 73% of pregnancies were
associated with at least 1 complication. Adverse
outcomes are shown in Table 1. OHSS was common
compared with rates reported in a population-based
study of deliveries resulting from prescribed fer-
tility treatments (18% vs. 1%) (4), although this com-
parison should be interpreted cautiously because the
populations and deﬁnitions for OHSS may differ.
Adverse cardiac maternal outcomes (27% vs. 13%)
and fetal or neonatal outcomes (45% vs. 20%) were
more common in this series compared with pregnant
women with heart disease not conceiving with ART
(2). Pre-maturity also was more common among in-
fants in this series compared with infants in a refer-
ence ART population (32% vs. 13%) (5).
This is the ﬁrst report of pregnancy outcomes in
women with heart disease conceiving by ART. This
report highlights the complex medical issues facing
modern maternal demographics. The results pre-
sented in this small series underscore the need for
updated information on outcomes in ART-treated
women with high-risk medical conditions.
OHSS is a potentially serious complication of ART
that may result in ﬂuid shifts, maternal hypotension,
thromboembolism, and death. Even mild forms of
OHSS may be poorly tolerated in women with ven-
tricular dysfunction, left ventricular outﬂow tract
obstruction, Fontan circulation, or pulmonary arterial
hypertension. Moreover, women with heart disease
may seek medical attention sooner than those free of
heart disease, leading to a high frequency of reported
OHSS. Although only women with successful preg-
nancies were included in this study, ART-treated
women with vulnerable heart lesions are at risk of
OHSS and thromboembolism, even if pregnancy is not
achieved.
Multiple gestations are common in ART pregnan-
cies and are associated with a higher cardiac output
compared with single pregnancies. This increased
hemodynamic burden can be problematic in women
with signiﬁcant left-sided obstructive valve lesions or
left ventricular systolic dysfunction. Multiple preg-
nancies have higher rates of pre-eclampsia and other
TABLE 1 Frequencies of Adverse Outcomes Stratiﬁed According to
Type of Cardiac Disease
Outcome
All
Pregnancies
(n ¼ 22)
Congenital
Lesions*
(n ¼ 15)
Acquired/
Arrhythmias†
(n ¼ 7)
ART outcome
Any ART outcome 4 (18) 4 (27) 0 (0)
OHSS 4 4 0
Thrombosis 0 0 0
Bleeding during ovum retrieval 0 0 0
Cardiac outcome
Any cardiac outcome 6 (27) 4 (27) 2 (29)
Maternal cardiac death 0 0 0
Arrhythmia 2 1 1
Congestive heart failure 4 3 1
Other 0 0 0
Obstetric outcome
Any obstetric outcome 8 (36) 6 (40) 2 (29)
Maternal noncardiac death 0 0 0
Post-partum hemorrhage 3 3 0
Antepartum hemorrhage or
subchorionic hematoma
4 3 1
Pre-eclampsia 2 1 1
Abruption 2 1 1
Fetal and neonatal outcome
Any fetal/neonatal outcome 10 (45) 8 (53) 2 (29)
Stillbirth 0 0 0
Neonatal death 1 1 0
Preterm birth‡ 7 5 2
Respiratory distress 1 1 0
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1863morbidities that are poorly tolerated in the setting of
pre-existing heart disease.
Pregnancies in women with heart disease are
associated with adverse fetal and neonatal outcomes
(2,3); the frequency of these complications may be
even higher in the presence of ART. Putative mech-
anisms include suboptimal endometrial function at
the time of implantation and compromised uteropla-
cental perfusion.
This study is limited by its retrospective design. It
is likely that not all women who had ART during the
time period studied were identiﬁed by chart review
because recruitment occurred in a cardiac clinic
where ART information was not routinely collected.
Current practice guidelines address pregnancy
risks in women with heart disease. However, more
information is urgently needed to help guide medical
and obstetric management of women with heart dis-
ease treated with ART. The additional potential risks
conferred by ART in conjunction with cardiac-speciﬁc
maternal and fetal risks must be weighed against the
desire for pregnancy. Modiﬁed ART protocols and
close antenatal surveillance at a center with expertise
in pregnancy and heart disease are recommended
because of high complication rates.
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Intracranial hemorrhage 1 1 0
Congenital anomalies 5 (23) 3 (20) 2 (29)
Cardiac anomaly§ 3 3 0
Noncardiac anomaly¶ 2 0 2
Values are n (%) of pregnancies with an outcome. Outcomes are not mutually exclusive. *Repaired
atrial septal defect with residual shunt (n ¼ 1), situs inversus/repaired atrial septal defect (n ¼ 1),
coarctation of the aorta (n ¼ 1), tetralogy of Fallot (n ¼ 3), repaired bicuspid aortic valve with
dilation of the aorta (n ¼ 1), bioprosthetic aortic valve for underlying bicuspid aortic valve disease
(n ¼ 1), Kartagener syndrome/situs inversus (n ¼ 1), pulmonary stenosis post-valvulotomy with
residual pulmonary regurgitation (n ¼ 2), and hypertrophic cardiomyopathy (n ¼ 4). †Mitral valve
prolapse with severe mitral regurgitation (n ¼ 1), mitral valve prolapse with mitral regurgitation
and biventricular systolic dysfunction (n ¼ 2 pregnancies, same woman), coronary artery disease
(n ¼ 1), supraventricular tachyarrhythmia (n ¼ 2), and ventricular tachycardia (n ¼ 1). ‡Singleton
delivery prior to 37 weeks and multiple delivery prior to 36 weeks. §Ventricular septal defect (n ¼
2) and situs inversus (n ¼ 1). ¶Omphalocele (n ¼ 1) and left unilateral coronal synostosis (n ¼ 1).
ART ¼ assisted reproductive technologies; OHSS ¼ ovarian hyperstimulation syndrome; SGA ¼
small for gestational age (birth weight <10th percentile for gestational age).Natalie Dayan, MD, MScy
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26:442–50.Early Intravenous Beta-
Blockade Before Primary
Percutaneous Coronary
Intervention Gives Major
Beneﬁts, Apparently
Without Side EffectsThe paper by Pizarro et al. (1) gives strong support
to the concept of very early low-cost intravenous
beta-blockade for primary percutaneous coronary
intervention (pPCI) and makes metoprolol the
agent of choice. When metoprolol was given to
patients with acute myocardial infarction (AMI) in
Killip class #II ST-segment elevation myocardial
infarction undergoing pPCI, there were fewer heart
failure admissions. The number needed to treat to
avoid 1 implantable cardioverter-deﬁbrillator was
only 8. Unexpectedly, there was no indication of
any side effects of beta-blockade. Were there really
none?
In the COMMIT (Clopidogrel and Metoprolol
in Myocardial Infarction Trial) study of 45,852 pa-
tients admitted to 1,250 hospitals within 24 h of
suspected AMI, patients were randomly allocated
metoprolol (up to 15 mg intravenous, then 200 mg
oral daily; n ¼ 22,929) or matching placebo (n ¼
22,923) (2). The use of early beta-blocker therapy
in AMI reduced the risks of reinfarction and ven-
tricular ﬁbrillation, yet cardiogenic shock was a
major side effect. Pizarro et al. (1) suggested starting
beta-blocker therapy only when the hemodynamic
condition had stabilized.
Yusuf (3) analyzed 28 trials involving approxi-
mately 27,500 patients during suspected early AMI.
Overall, he concluded that intravenous plus oral
beta-blockade reduced the risk for early death,
reinfarction, and ventricular ﬁbrillation by approxi-
mately 15% (3). He suggested that the reduction in
mortality was greatest for those treated within 2 h
of pain. The treated group had few side effects,
namely reversible and nonfatal heart block and
hypotension.
Thus in 2 large studies, beta-blockade had side-
effects to which clinicians should be alerted when
considering the use of beta-blockers for early AMI.*Lionel H. Opie, MD, DPhil
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Postgrad Med 1988;Spec No:90–5.REPLY: Early Intravenous Beta-Blockade
Before Primary Percutaneous Coronary
Intervention Gives Major Beneﬁts Apparently
Without Side EffectsWe appreciate the comment by our admired Professor
Opie regarding the potential side effects of early
intravenous (IV) beta-blockers in patients with
ST-segment elevation myocardial infarction (STEMI).
Our paper described the long-term follow-up of pa-
tients in the METOCARD-CNIC (Effect of Metoprolol
in Cardioprotection During an Acute Myocardial
Infarction) trial (1). The acute effects of IV metoprolol
in this trial were reported in a previous publication
(2). In the ﬁrst publication, we described the inci-
dence of adverse events during admission (those that
can be ascribed to an acute single administration of IV
metoprolol before primary angioplasty): death during
admission (2.1% vs. 2.3% in IV metoprolol vs. control,
respectively), advanced atrioventricular block (0.7%
vs. 1.5%), cardiogenic shock (4.3% vs. 5.4%), and
ventricular tachycardia/ﬁbrillation (3.6% vs. 7.7%).
Thus, it is not correct that there were no side effects
of beta-blockade in our study; rather, we presented
that metoprolol was not associated with an excess
number of these side effects.
The role of early IV beta-blockade in STEMI was
mostly evaluated long ago, and the side effect proﬁle
has been dramatically changed within the last few
years. The METOCARD-CNIC trial was the ﬁrst ran-
domized trial performed in patients with STEMI un-
dergoing reperfusion by primary angioplasty. One of
Dr. Opie’s references to support the potential increase
in side effect frequency is from Yusuf reporting a
